Nothing in that presentation we all didn't already know. I could easily present the next one if required. I'm left wondering how 'prestigious' QIDP really is if it was awarded for a compound that then requires another year of testing/data just to define to the FDA exactly what type of compound it is? How is it 'fast-tracked' when it still needs to go through years of human trials like every other drug? These are genuine questions that have occurred to me after following this company for some time.
Ann: Recce Presented at FNN/Shaw and Partners Investor Conference, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.010(2.90%) |
Mkt cap ! $96.87M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 34.5¢ | 33.5¢ | $7.822K | 22.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9482 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 77675 | 1 |
View Market Depth
| Last trade - 15.47pm 21/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |